MedTrace Logo

CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML）

NCT03556982 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-06-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficiency of CD123-Targeted CAR-T in Treating Patients with relapsed/refractory AML

Conditions

  • Leukemia, Myeloid, Acute

Interventions

BIOLOGICAL

CART-123 cells

CD123-Targeted CAR-T cells are infused to patient received FC chemotherapy

Sponsors & Collaborators

  • The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

    lead OTHER

Principal Investigators

  • HUISHENG AI · 307 Hospital of PLA

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2019-03-01
Completion
2020-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03556982 on ClinicalTrials.gov